Trials / Completed
CompletedNCT04013243
Effect of Magnesium on Dose of Rocuronium for Deep Neuromuscular Blockade
Effect of Magnesium on Maintenance Dose of Rocuronium for Deep Neuromuscular Blockade During Robotic Radical Prostatectomy
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 68 (actual)
- Sponsor
- Seoul National University Bundang Hospital · Academic / Other
- Sex
- Male
- Age
- 20 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
It is well known that magnesium enhances the effect of neuromuscular blocking agents such as rocuronium. However, it is not known how much magnesium can reduce neuromuscular blocking agents in maintaining deep neuromuscular blockade. Through this study, the investigators will quantitatively analyze the rocuronium saving effect of magnesium.
Detailed description
It is well known that magnesium potentiate the effect of neuromuscular blocking agents. It prolonged the duration of rocuronium and reduces the onset time of rocuronium. Magnesium acts on motor end plate, where magnesium reduces the release of prejunctional acetylcholine, thereby decreasing the muscle membrane excitability. However, the quantitative rocuronium saving effect of magnesium is not clear. This study's hypothesis is that magnesium would reduce the amount of rocuronium. And the investigators want to evaluate how much magnesium can reduce the amount of rocuronium. Secondary outcome is the effects of magnesium on recovery time, postoperative pain, nausea and vomiting.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Magnesium Sulfate | magnesium sulphate 50mg/kg in normal saline 50ml infusion for 10minutes for loading dose followed by 15mg/kg/hr for continuous infusion |
| DRUG | Placebo | Normal Saline 50ml infusion for loading dose followed by continuous infusion for same dose of magnesium. |
Timeline
- Start date
- 2019-04-26
- Primary completion
- 2019-07-30
- Completion
- 2019-07-30
- First posted
- 2019-07-09
- Last updated
- 2020-12-24
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04013243. Inclusion in this directory is not an endorsement.